Muse Diagnostics is a medical device startup based in Bengaluru, India, that makes the Taal digital stethoscope for telemedicine companies and remote patient monitoring.

This Startup Deep Dive explains what Muse Diagnostics does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Muse Diagnostics in Brief

• What it is: Muse Diagnostics is an Indian Digital stethoscope medtech company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company makes the Taal digital stethoscope, which records, filters and shares body sounds; it connects via USB-C or an audio jack and works with companion software (eMurmur / Surr app).
• The original 2017 design featured electronic and mechanical filtering, a screen showing heart rate and battery, instant-on use and fewer than three buttons.
• A mobile app records, analyses and securely shares body sounds, with telemedicine integration and learning features.
• Funding: reports differ: about USD 840K across five rounds (one tracker) vs about USD 70K (another).

Muse Diagnostics Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Muse Diagnostics?

Muse Diagnostics operates in the Digital stethoscope medtech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Muse Diagnostics.

• The company makes the Taal digital stethoscope, which records, filters and shares body sounds; it connects via USB-C or an audio jack and works with companion software (eMurmur / Surr app).
• The original 2017 design featured electronic and mechanical filtering, a screen showing heart rate and battery, instant-on use and fewer than three buttons.
• A mobile app records, analyses and securely shares body sounds, with telemedicine integration and learning features.
• Devices are aimed at telemedicine, remote patient monitoring and medical education.

The Origin Story of Muse Diagnostics

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Arvind Badrinarayanan, Sumukh Mysore.
• Bengaluru-based Muse (MUSEinc) was described in 2017 as founded in 2014, working on open-source technologies for affordable diagnostics.
• Dr Arvind Badrinarayanan, a veterinarian and CEO, began experimenting with digital stethoscopes in his final year of veterinary college to block ambient animal noise; he met co-founder Sumukh Mysore (CTO) at a Bengaluru recording studio.
• Taal was developed over more than two years as a prototype in a makerspace run by the NGO Project DEFY in rural Bengaluru.
• Later profiles date the Taal concept to 2016 and describe the team as a veterinarian, a sound engineer and a geneticist.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Digital stethoscope medtech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2014 or 2016: company/Taal concept begins (reports differ).
• 2017: about USD 5,000 raised through Indiegogo pre-sales; three new investors put in nearly Rs 23 lakh; bootstrapped until May 2017; distribution agreement with the NGO Aarogya Seva.
• June 2020: pre-seed round of USD 37,000 from Brinc (reported).
• June 2021: sales commenced (reported).
• 2021: undisclosed seed funding from Beyond Next Ventures; over 100 units sold within two months, mainly to telemedicine companies (reported).
• July 2024: incubator/accelerator round linked to I-HEAL @ ISB (reported).

Muse Diagnostics Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• 2017: about USD 5,000 from Indiegogo pre-sales plus nearly Rs 23 lakh from three individual investors (a US veterinarian and a Bengaluru blockchain expert among them).
• Pre-seed, USD 37,000, Brinc, June 2020 (reported).
• Seed, undisclosed, Beyond Next Ventures, 2021 (reported; dated August-September 2021 by trackers).
• Other listed backers include I-HEAL @ ISB, BIRAC BIG grant and I-Venture (one tracker).
• The 2017 plan was to seek a first seed round of over half a million dollars.

How Does Muse Diagnostics Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells connected medical devices, primarily to telemedicine companies, rural healthcare NGOs and educators.
• Price at the 2017 plan was about USD 50 / Rs 3,500; a later report said Taal sells at Rs 8,800 or on a pay-per-use SaaS model.

The Numbers: Muse Diagnostics Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Over 100 units sold in the first two months of sales in 2021 (reported).
• Total funding reported at about USD 840K (one tracker) vs about USD 70K (another).
• No revenue or profit figures found.

Market Opportunity for Muse Diagnostics

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Focused on telemedicine, remote patient monitoring and medical education, with customers mainly in India and Southeast Asia.
• The 2017 plan canvassed South Korea, Japan, Australia, the EU, Singapore and North America; a data profile mentions planned expansion to Southeast Asia and possibly Africa by 2023.

Technology and Product at Muse Diagnostics

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Digital stethoscope with electronic and mechanical filtering of heart and lung sounds, USB-C or audio-jack output, and software for analysing, recording and sharing auscultation data.
• Companion software offers auscultation and consultation modes with noise cancellation.

Team and Culture at Muse Diagnostics

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Dr Arvind Badrinarayanan, co-founder and CEO; Sumukh Mysore, co-founder and CTO.
• A 2017 article also named Anjali Rajan (Chief Innovation Officer) and Shilpa Prabhudeva (Chief Product Officer).
• Directory listings put the team at about 7 to 8 people (sources differ).

Muse Diagnostics Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Muse Diagnostics

• Very small team and modest reported funding relative to the scale of the medtech market.
• Competition from better-funded global digital stethoscope makers.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Muse Diagnostics Growth Outlook: What to Watch

• The 2017 plan listed future products such as AdiTaal and other diagnostic devices.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Muse Diagnostics can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Muse Diagnostics Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Muse Diagnostics

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Muse Diagnostics.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Muse Diagnostics

Studying a company in the Digital stethoscope medtech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Muse Diagnostics.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Muse Diagnostics as a Startup

• Customer clarity: Can Muse Diagnostics name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Muse Diagnostics is part of India’s growing Digital stethoscope medtech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Muse Diagnostics FAQs: Frequently Asked Questions

What is Muse Diagnostics?

Muse Diagnostics is a medical device startup based in Bengaluru, India, that makes the Taal digital stethoscope for telemedicine companies and remote patient monitoring. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Muse Diagnostics?

Muse Diagnostics was founded by Arvind Badrinarayanan, Sumukh Mysore, and the company reports a founding year of reports differ: 2014 (company profile at the time) or 2016 (Taal concept, per later profiles).

How much funding has Muse Diagnostics raised?

reports differ: about USD 840K across five rounds (one tracker) vs about USD 70K (another). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Muse Diagnostics make money?

Muse Diagnostics earns revenue from its Digital stethoscope medtech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Muse Diagnostics?

Reported rivals include Eko, StethoMe, Strados Labs. See the competitor comparison above for how they differ.

What are the main risks for Muse Diagnostics?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Ftcash — Ftcash: payments and loans for India’s micro-merchants | Freed — Freed raised Rs 60 crore Series A for debt settlement. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.